Colchicine

Generic Name
Colchicine
Brand Names
Colcrys, Gloperba, Lodoco, Mitigare
Drug Type
Small Molecule
Chemical Formula
C22H25NO6
CAS Number
64-86-8
Unique Ingredient Identifier
SML2Y3J35T
Background

Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammato...

Indication

Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established ather...

Associated Conditions
Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke
Associated Therapies
-
Clinical Trials
Related News
globenewswire.com
·

Scilex Bio, a Controlling Interest of Joint Venture

KDS2010 (Tisolagiline), a reversible selective monoamine oxidase B (MAO-B) inhibitor, is being studied for treating Alzheimer's disease by influencing astrocytic GABA inhibition. It attenuates astrocytic GABA levels, enhances synaptic transmission, and improves learning and memory in mouse models. A Phase 2 clinical trial is currently recruiting in South Korea, with a U.S. cohort to be added in 2025. The Alzheimer’s drug market is projected to exceed $15 billion by 2030.
theglobeandmail.com
·

Scilex Holding Company Announces Presentation of Data at the 2024 American College of ...

Scilex Holding Company announced data presentation on GLOPERBA® (colchicine oral solution) at the 2024 American College of Rheumatology Convergence, highlighting its precision dosing for gout patients, including reduced daily dose for severe renal impairment.
biospace.com
·

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company ...

Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission upon Phase III trials completion for SP-103, a next-generation lidocaine topical system for chronic neck pain. Market research projects SP-103's peak sales potential at $1.2 billion annually by the 6th year post-launch.
globenewswire.com
·

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of

Scilex Holding Company announces successful Phase II meeting with FDA, paving the way for NDA submission for SP-103, a triple-strength lidocaine topical system for chronic neck pain. Market research projects SP-103 could achieve $1.2 billion in annual sales by the 6th year post-launch.
globenewswire.com
·

Scilex Holding Company Announces that its Board of

Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido® for neuropathic pain, ELYXYB® for migraine, and Gloperba® for gout. A next-generation product, SP-103, targets acute pain with projected peak sales of $1.2 billion.
morningstar.com
·

Scilex Holding Company Announces that its Board of Directors has Authorized Management ...

Scilex Holding Company explores spinoff or public listing of Scilex Pharmaceuticals in markets including Hong Kong to unlock potential value. Scilex Pharma has three FDA-approved products: ZTlido®, ELYXYB®, and Gloperba®, with SP-103, a next-generation lidocaine topical system, targeting $1.2 billion in peak sales.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy